Friday, July 10, 2026

pharma · Multiple Myeloma · Ovarian Cancer

pharma&

pharmaand is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s

Vienna, AT HQ
2017 Founded
210 Employees
EMA registrant Type
Company details
Clinical program

Rucaparib

Phase 3 · small molecule · Ovarian Cancer

Rucaparib for Ovarian Cancer is a Phase 3 program (small_molecule) at pharmaand GmbH with 1 ClinicalTrials.gov record(s).

← All pharmaand GmbH projects Phase 3 small molecule completed

Internal code CO-338-014

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
pharmaand GmbH
Phase
Phase 3
Modality
small_molecule
Indication
Ovarian Cancer
Status
completed
Trials
1

Clinical trials